Trepulmix
What Trepulmix is used for
Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Trepulmix
- Active substance
- treprostinil
- Disease area
- Hypertension, Pulmonary
- Medicine group
- Antithrombotic agents
- ATC code
- B01AC21
- Marketing authorisation holder
- SciPharm Sàrl
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Yutrepia
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Trepulmix used for?
Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
What is the active substance in Trepulmix?
Trepulmix contains treprostinil.
Who makes Trepulmix?
The EU marketing authorisation holder is SciPharm Sàrl.
Is Trepulmix an orphan medicine?
Yes. Trepulmix is designated an orphan medicine in the EU, for a rare disease (Hypertension, Pulmonary).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU